Fundraising FoxLucius Partners
Venture capitalActively deployingNew York · 3 people tracked
Find your way into Lucius Partners
Fund manager profile
Lucius Partners is a venture fund manager based in New York. SEC filings show 1 venture fund on record, most recently Lucius Partners Opportunity Fund, LP ($20M offering) filed October 2025.
Source: SEC EDGAR Form D filings. Firm website data not yet available.
Team · 3 people
from public directories
What they invest in
from 4 of 4 portfolio companiesBiotech ×3Consumer ×1Deep Tech ×1Healthtech ×1Medical Devices ×1Wellness & Fitness ×1
HQs:United States×4
Investments · 4 tracked
founders shown can be your intro pathBy year:2025 · 12023 · 23 dated
Adapt Biotechnologies develops the BRiTE platform, a bispecific antibody technology designed to treat brain tumors and intracerebral malignancies by activating T cells to target and destroy glioma cells.
BiotechDeep TechHealthtechMedical DevicesCharlotte, US
Michael J. Roberts(Chief Executive Officer and Director)inL. Arthur Hewitt(Chief Development Officer)Michael Roberts(President and Chief Executive Officer)inSimon Pedder(Executive Chairman)Timothy L. Maness(Chief Financial Officer)
BoardAnthony Zook(Director)
Shine AyG is a skin care studio offering eyebrow design services, including microblading, and premium skincare treatments.
ConsumerWellness & FitnessBoca Raton, US
Jane Gottschalk(President, Chief Creative Officer and Director)inChath Weerasinghe(Chief Financial Officer and Chief Operating Officer)inMark N. Tompkins(Director)Ian Jacobs(Executive Officer, Director)
Co-investorsVedra Partners
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 2
2 IPOsAdaptin BIOOTC: APTNPerfect MomentOTC: PMNT
IPO stake values · per SEC filings · 2
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Adaptin BIO | 40.1% | $4.40 | Jul 2025 | $14.3M |
| Perfect Moment | 4.5% | $6.00 | Feb 2024 | $4.2M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- Where is Lucius Partners located?
- Lucius Partners is headquartered in New York, US.